CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVMGet Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock.

CEL-SCI Price Performance

Shares of CVM stock opened at $2.40 on Thursday. The firm has a market capitalization of $104.98 million, a PE ratio of -2.82 and a beta of 1.72. The company has a current ratio of 4.30, a quick ratio of 3.91 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average price of $2.71. CEL-SCI has a one year low of $1.88 and a one year high of $6.14.

CEL-SCI (NYSE:CVMGet Rating) last announced its quarterly earnings results on Wednesday, December 28th. The company reported ($0.21) EPS for the quarter. As a group, equities research analysts anticipate that CEL-SCI will post 0.29 EPS for the current fiscal year.

CEL-SCI Company Profile

(Get Rating)

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers.

Featured Articles

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.